RGEN
Repligen Corporation
Price Chart
Latest Quote
$132.02
-1.53 (-1.15%)
Current Price
| Previous Close | $133.55 |
| Open | $131.40 |
| Day High | $133.57 |
| Day Low | $127.48 |
| Volume | 1,236,920 |
Stock Information
| Shares Outstanding | 56.41M |
| Total Debt | $687.62M |
| Cash Equivalents | $784.53M |
| Revenue | $763.34M |
| Net Income | $51.40M |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $7.45B |
| P/E Ratio | 145.08 |
| EPS (TTM) | $0.91 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.35B |
| Sales | $763.34M |
| Income | $51.40M |
| Book/sh | $37.33 |
| Cash/sh | $13.91 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 7.45 |
| Current Ratio | 9.20 |
| Debt/Eq | 32.66 |
| EPS Growth TTM | 42.90% |
Returns & Margins
| ROA | 1.18% |
| ROE | 2.51% |
| Gross Margin | 53.14% |
| Operating Margin | 8.90% |
| Profit Margin | 6.73% |
Ownership
| Insider Ownership | 5.25% |
| Institutional Ownership | 119.70% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 51.86 |
| PEG | 2.08 |
| P/S | 9.76 |
| P/B | 3.54 |
Analyst Data
| Recommendation | none |
| Target Price | $176.11 |
Technical Indicators
| SMA20 | $124.83 |
| SMA50 | $121.44 |
| SMA200 | $138.19 |
| RSI | 63.13 |
| ATR | 5.5650 |
| Shares Float | 53.36M |
| Short Float | 10.60% |
| Short Ratio | 4.33 |
| Volatility | 1.08 |
| Rel Volume | 1.27 |
Performance History
| Week | -0.98% |
| Month | +21.66% |
| Quarter | +12.25% |
| 6 Months | -16.49% |
| YTD | -19.67% |
| Year | +9.10% |
| 3 Years | -20.09% |
| 5 Years | -31.07% |
| 10 Years | +487.54% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $132.02 | 1,236,900 |
| 2026-06-17 | $133.55 | 1,352,500 |
| 2026-06-16 | $131.69 | 612,400 |
| 2026-06-15 | $130.87 | 633,200 |
| 2026-06-12 | $130.59 | 1,338,000 |
| 2026-06-11 | $133.33 | 647,100 |
| 2026-06-10 | $130.76 | 1,212,400 |
| 2026-06-09 | $130.13 | 1,472,800 |
| 2026-06-08 | $125.33 | 741,300 |
| 2026-06-05 | $122.31 | 693,700 |
| 2026-06-04 | $126.55 | 1,205,200 |
| 2026-06-03 | $121.73 | 663,400 |
| 2026-06-02 | $121.13 | 769,600 |
| 2026-06-01 | $123.10 | 695,100 |
| 2026-05-29 | $123.95 | 925,600 |
| 2026-05-28 | $122.73 | 1,595,800 |
| 2026-05-27 | $113.17 | 1,125,500 |
| 2026-05-26 | $115.19 | 800,000 |
| 2026-05-22 | $115.06 | 722,900 |
| 2026-05-21 | $113.37 | 1,042,700 |
| 2026-05-20 | $111.74 | 1,182,500 |
| 2026-05-19 | $108.52 | 2,216,900 |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
đ° Latest News
2 Profitable Stocks on Our Watchlist and 1 Facing Challenges
StockStory âĸ 2026-06-19T13:16:58Z
Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools
Insider Monkey âĸ 2026-06-19T12:48:47Z
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-04T15:30:26Z
3 Out-of-Favor Stocks We Keep Off Our Radar
StockStory âĸ 2026-05-23T09:24:55Z
3 Stocks That May Be Trading Below Their Estimated Value In May 2026
Simply Wall St. âĸ 2026-05-22T11:38:01Z
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks
StockStory âĸ 2026-05-20T23:24:55Z
Why Repligen (RGEN) Stock Is Trading Up Today
StockStory âĸ 2026-05-19T15:00:55Z
1 Growth Stock with Explosive Upside and 2 Facing Headwinds
StockStory âĸ 2026-05-19T12:28:55Z
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
StockStory âĸ 2026-05-17T09:56:55Z
3 Small-Cap Stocks We Steer Clear Of
StockStory âĸ 2026-05-15T13:08:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $352,011,000 | $359,794,000 | $353,922,000 | $345,830,000 |
| Cost Of Revenue | $352,011,000 | $359,794,000 | $353,922,000 | $345,830,000 |
| Total Revenue | $738,256,000 | $634,439,000 | $632,362,000 | $801,536,000 |
| Operating Revenue | $738,256,000 | $634,439,000 | $632,362,000 | $801,536,000 |
| Expenses | ||||
| Interest Expense | $21,513,000 | $20,731,000 | $2,503,000 | $1,162,000 |
| Total Expenses | $696,696,000 | $666,362,000 | $615,228,000 | $605,595,000 |
| Other Income Expense | $43,996,000 | $27,462,000 | $50,151,000 | $26,176,000 |
| Other Non Operating Income Expenses | $2,815,000 | $-5,174,000 | $8,123,000 | $-9,531,000 |
| Net Non Operating Interest Income Expense | $-23,173,000 | $-22,574,000 | $-10,578,000 | $-2,977,000 |
| Total Other Finance Cost | $1,660,000 | $1,843,000 | $8,075,000 | $1,815,000 |
| Interest Expense Non Operating | $21,513,000 | $20,731,000 | $2,503,000 | $1,162,000 |
| Operating Expense | $344,685,000 | $306,568,000 | $261,306,000 | $259,765,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Net Interest Income | $-23,173,000 | $-22,574,000 | $-10,578,000 | $-2,977,000 |
| Normalized Income | $16,608,096 | $-56,322,384 | $9,202,416 | $155,643,757 |
| Net Income From Continuing And Discontinued Operation | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Total Operating Income As Reported | $55,167,000 | $-35,114,000 | $47,703,000 | $224,670,000 |
| Net Income Common Stockholders | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Net Income | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Net Income Including Noncontrolling Interests | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Net Income Continuous Operations | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Pretax Income | $62,383,000 | $-27,035,000 | $56,707,000 | $219,140,000 |
| Special Income Charges | $13,607,000 | $-3,191,000 | $17,893,000 | $28,729,000 |
| Operating Income | $41,560,000 | $-31,923,000 | $17,134,000 | $195,941,000 |
| Gross Profit | $386,245,000 | $274,645,000 | $278,440,000 | $455,706,000 |
| Per Share | ||||
| Diluted EPS | $0.86 | $-0.46 | $0.74 | $3.24 |
| Basic EPS | $0.87 | $-0.46 | $0.75 | $3.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $8,895,096 | $1,827,616 | $15,634,416 | $5,391,757 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $139,671,000 | $47,622,000 | $103,296,000 | $241,607,000 |
| Total Unusual Items | $41,181,000 | $32,636,000 | $42,028,000 | $35,707,000 |
| Total Unusual Items Excluding Goodwill | $41,181,000 | $32,636,000 | $42,028,000 | $35,707,000 |
| Reconciled Depreciation | $96,956,000 | $86,562,000 | $86,114,000 | $57,012,000 |
| EBITDA (Bullshit earnings) | $180,852,000 | $80,258,000 | $145,324,000 | $277,314,000 |
| EBIT | $83,896,000 | $-6,304,000 | $59,210,000 | $220,302,000 |
| Diluted Average Shares | $56,561,000 | $55,936,751 | $56,377,319 | $57,455,275 |
| Basic Average Shares | $56,234,000 | $55,936,751 | $55,719,860 | $55,460,232 |
| Diluted NI Availto Com Stockholders | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Tax Provision | $13,489,000 | $-1,521,000 | $21,111,000 | $33,181,000 |
| Restructuring And Mergern Acquisition | $-13,607,000 | $3,191,000 | $-30,569,000 | $-28,729,000 |
| Gain On Sale Of Security | $27,574,000 | $35,827,000 | $24,135,000 | $6,978,000 |
| Research And Development | $54,177,000 | $43,200,000 | $42,722,000 | $43,936,000 |
| Selling General And Administration | $290,508,000 | $263,368,000 | $218,584,000 | $215,829,000 |
| Other Special Charges | - | - | $12,676,000 | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $605,574,000 | $543,826,000 | $570,768,000 | $694,569,000 |
| Total Assets | $2,949,699,000 | $2,829,666,000 | $2,831,185,000 | $2,531,600,000 |
| Total Non Current Assets | $1,812,314,000 | $1,763,625,000 | $1,719,839,000 | $1,533,482,000 |
| Other Non Current Assets | $4,913,000 | $868,000 | $1,277,000 | $815,000 |
| Non Current Deferred Assets | $694,000 | $749,000 | $1,530,000 | $840,000 |
| Non Current Deferred Taxes Assets | $694,000 | $749,000 | $1,530,000 | $840,000 |
| Goodwill And Other Intangible Assets | $1,500,555,000 | $1,428,892,000 | $1,394,077,000 | $1,216,131,000 |
| Other Intangible Assets | $386,147,000 | $397,897,000 | $406,957,000 | $360,618,000 |
| Current Assets | $1,137,385,000 | $1,066,041,000 | $1,111,346,000 | $998,118,000 |
| Other Current Assets | $27,143,000 | $20,597,000 | $19,922,000 | $17,409,000 |
| Prepaid Assets | $13,569,000 | $11,010,000 | $13,619,000 | $2,428,000 |
| Inventory | $170,458,000 | $142,964,000 | $202,321,000 | $238,277,000 |
| Receivables | $158,587,000 | $134,115,000 | $124,161,000 | $116,247,000 |
| Accounts Receivable | $158,587,000 | $134,115,000 | $124,161,000 | $116,247,000 |
| Allowance For Doubtful Accounts Receivable | $-2,767,000 | $-1,832,000 | $-2,122,000 | $-1,365,000 |
| Gross Accounts Receivable | $161,354,000 | $135,947,000 | $126,283,000 | $117,612,000 |
| Cash Cash Equivalents And Short Term Investments | $767,628,000 | $757,355,000 | $751,323,000 | $623,757,000 |
| Cash And Cash Equivalents | $566,021,000 | $757,355,000 | $751,323,000 | $523,458,000 |
| Debt | ||||
| Total Debt | $689,948,000 | $686,247,000 | $711,804,000 | $422,961,000 |
| Long Term Debt And Capital Lease Obligation | $668,389,000 | $671,143,000 | $636,721,000 | $131,389,000 |
| Long Term Debt | $542,213,000 | $525,567,000 | $510,143,000 | - |
| Current Debt And Capital Lease Obligation | $21,559,000 | $15,104,000 | $75,083,000 | $291,572,000 |
| Current Debt | - | - | $69,452,000 | $284,615,000 |
| Other Current Borrowings | - | - | $69,452,000 | $284,615,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $843,570,000 | $856,948,000 | $866,340,000 | $620,900,000 |
| Total Non Current Liabilities Net Minority Interest | $707,744,000 | $730,161,000 | $701,398,000 | $216,704,000 |
| Other Non Current Liabilities | $16,859,000 | $36,243,000 | $25,353,000 | $62,315,000 |
| Non Current Deferred Liabilities | $22,496,000 | $22,775,000 | $39,324,000 | $23,000,000 |
| Non Current Deferred Taxes Liabilities | $22,496,000 | $22,775,000 | $39,324,000 | $23,000,000 |
| Current Liabilities | $135,826,000 | $126,787,000 | $164,942,000 | $404,196,000 |
| Other Current Liabilities | $5,049,000 | $17,126,000 | $12,983,000 | $13,950,000 |
| Current Deferred Liabilities | $14,609,000 | $13,243,000 | $17,067,000 | $19,283,000 |
| Payables And Accrued Expenses | $54,468,000 | $49,151,000 | $43,149,000 | $45,869,000 |
| Payables | $33,602,000 | $33,557,000 | $26,377,000 | $30,013,000 |
| Total Tax Payable | $3,592,000 | $1,423,000 | $6,814,000 | $2,459,000 |
| Income Tax Payable | $3,592,000 | $1,423,000 | $6,814,000 | $2,459,000 |
| Accounts Payable | $30,010,000 | $32,134,000 | $19,563,000 | $27,554,000 |
| Equity | ||||
| Common Stock Equity | $2,106,129,000 | $1,972,718,000 | $1,964,845,000 | $1,910,700,000 |
| Total Equity Gross Minority Interest | $2,106,129,000 | $1,972,718,000 | $1,964,845,000 | $1,910,700,000 |
| Stockholders Equity | $2,106,129,000 | $1,972,718,000 | $1,964,845,000 | $1,910,700,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,531,000 | $-52,533,000 | $-37,808,000 | $-34,394,000 |
| Other Equity Adjustments | $-2,531,000 | $-52,533,000 | $-37,808,000 | $-34,394,000 |
| Retained Earnings | $456,248,000 | $407,354,000 | $432,868,000 | $397,272,000 |
| Other | ||||
| Ordinary Shares Number | $56,325,429 | $56,091,677 | $55,766,078 | $55,557,698 |
| Share Issued | $56,325,429 | $56,091,677 | $55,766,078 | $55,557,698 |
| Tangible Book Value | $605,574,000 | $543,826,000 | $570,768,000 | $694,569,000 |
| Invested Capital | $2,648,342,000 | $2,498,285,000 | $2,544,440,000 | $2,195,315,000 |
| Working Capital | $1,001,559,000 | $939,254,000 | $946,404,000 | $593,922,000 |
| Capital Lease Obligations | $147,735,000 | $160,680,000 | $132,209,000 | $138,346,000 |
| Total Capitalization | $2,648,342,000 | $2,498,285,000 | $2,474,988,000 | $1,910,700,000 |
| Additional Paid In Capital | $1,651,849,000 | $1,617,336,000 | $1,569,227,000 | $1,547,266,000 |
| Capital Stock | $563,000 | $561,000 | $558,000 | $556,000 |
| Common Stock | $563,000 | $561,000 | $558,000 | $556,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $126,176,000 | $145,576,000 | $126,578,000 | $131,389,000 |
| Current Deferred Revenue | $14,609,000 | $13,243,000 | $17,067,000 | $19,283,000 |
| Current Capital Lease Obligation | $21,559,000 | $15,104,000 | $5,631,000 | $6,957,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $40,141,000 | $32,163,000 | $16,660,000 | $33,522,000 |
| Current Accrued Expenses | $20,866,000 | $15,594,000 | $16,772,000 | $15,856,000 |
| Goodwill | $1,114,408,000 | $1,030,995,000 | $987,120,000 | $855,513,000 |
| Net PPE | $306,152,000 | $333,116,000 | $322,955,000 | $315,696,000 |
| Accumulated Depreciation | $-203,882,000 | $-162,467,000 | $-128,723,000 | $-92,307,000 |
| Gross PPE | $510,034,000 | $495,583,000 | $451,678,000 | $408,003,000 |
| Leases | $151,121,000 | $145,256,000 | $126,663,000 | $115,672,000 |
| Construction In Progress | $28,401,000 | $28,211,000 | $47,086,000 | $31,553,000 |
| Other Properties | $267,488,000 | $266,295,000 | $230,665,000 | $220,056,000 |
| Machinery Furniture Equipment | $61,697,000 | $54,322,000 | $44,605,000 | $38,120,000 |
| Buildings And Improvements | $763,000 | $675,000 | $1,667,000 | $1,599,000 |
| Land And Improvements | $564,000 | $824,000 | $992,000 | $1,003,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $55,033,000 | $56,214,000 | $74,231,000 | $82,656,000 |
| Work In Process | $20,793,000 | $4,542,000 | $4,492,000 | $6,183,000 |
| Raw Materials | $94,632,000 | $82,208,000 | $123,598,000 | $149,438,000 |
| Other Short Term Investments | $201,607,000 | $0 | $0 | $100,299,000 |
| Treasury Shares Number | - | - | $0 | - |
| Foreign Currency Translation Adjustments | - | - | - | $-34,394,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $91,687,000 | $142,489,000 | $74,930,000 | $38,737,000 |
| Operating Activities | ||||
| Operating Cash Flow | $117,417,000 | $175,394,000 | $113,918,000 | $172,083,000 |
| Cash Flow From Continuing Operating Activities | $117,417,000 | $175,394,000 | $113,918,000 | $172,083,000 |
| Operating Gains Losses | - | $3,596,000 | $12,676,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-25,730,000 | $-32,905,000 | $-38,988,000 | $-133,346,000 |
| Investing Cash Flow | $-298,474,000 | $-86,383,000 | $-123,275,000 | $-233,236,000 |
| Cash Flow From Continuing Investing Activities | $-298,474,000 | $-86,383,000 | $-123,275,000 | $-233,236,000 |
| Net Other Investing Changes | $-2,397,000 | $1,287,000 | $32,000 | $110,000 |
| Capital Expenditure Reported | $-2,211,000 | $-4,222,000 | $-2,766,000 | $-3,512,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-14,386,000 | $0 |
| Financing Cash Flow | $-15,205,000 | $-82,902,000 | $248,961,000 | $-13,337,000 |
| Cash Flow From Continuing Financing Activities | $-15,205,000 | $-82,902,000 | $248,961,000 | $-13,337,000 |
| Net Other Financing Charges | $-18,381,000 | $-17,257,000 | $-27,823,000 | $-17,044,000 |
| Net Common Stock Issuance | $0 | $0 | $-14,386,000 | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-69,939,000 | $0 | $0 |
| Issuance Of Debt | $0 | $0 | $290,094,000 | $0 |
| End Cash Position | $566,021,000 | $757,355,000 | $751,323,000 | $523,458,000 |
| Beginning Cash Position | $757,355,000 | $751,323,000 | $523,458,000 | $603,814,000 |
| Effect Of Exchange Rate Changes | $4,928,000 | $-77,000 | $-11,739,000 | $-5,866,000 |
| Changes In Cash | $-196,262,000 | $6,109,000 | $239,604,000 | $-74,490,000 |
| Proceeds From Stock Option Exercised | $3,176,000 | $4,294,000 | $1,076,000 | $3,707,000 |
| Common Stock Payments | $0 | $0 | $-14,386,000 | $0 |
| Net Issuance Payments Of Debt | $0 | $-69,939,000 | $290,094,000 | $0 |
| Net Long Term Debt Issuance | $0 | $-69,939,000 | $290,094,000 | $0 |
| Long Term Debt Payments | $0 | $-69,939,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $0 | $290,094,000 | $0 |
| Net Investment Purchase And Sale | $-200,257,000 | $0 | $102,323,000 | $-100,000,000 |
| Sale Of Investment | $0 | $0 | $102,323,000 | $0 |
| Purchase Of Investment | $-200,257,000 | $0 | $0 | $-100,000,000 |
| Net Business Purchase And Sale | $-70,328,000 | $-54,765,000 | $-186,642,000 | $0 |
| Purchase Of Business | $-70,328,000 | $-54,765,000 | $-186,642,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-3,006,000 | $0 | $-45,000,000 |
| Purchase Of Intangibles | $0 | $-3,006,000 | $0 | $-45,000,000 |
| Net PPE Purchase And Sale | $-23,281,000 | $-25,677,000 | $-36,222,000 | $-84,834,000 |
| Sale Of PPE | $238,000 | $0 | $0 | - |
| Purchase Of PPE | $-23,519,000 | $-25,677,000 | $-36,222,000 | $-84,834,000 |
| Change In Working Capital | $-50,880,000 | $60,921,000 | $-20,095,000 | $-69,838,000 |
| Change In Other Current Liabilities | $-17,115,000 | $-2,971,000 | $-12,641,000 | $-987,000 |
| Change In Other Current Assets | $-1,560,000 | $471,000 | $-461,000 | $-231,000 |
| Change In Payables And Accrued Expense | $7,663,000 | $19,004,000 | $-31,321,000 | $-10,216,000 |
| Change In Accrued Expense | $11,813,000 | $6,106,000 | $-21,518,000 | $-2,019,000 |
| Change In Payable | $-4,150,000 | $12,898,000 | $-9,803,000 | $-8,197,000 |
| Change In Account Payable | $-4,150,000 | $12,898,000 | $-9,803,000 | $-8,197,000 |
| Change In Prepaid Assets | $-7,756,000 | $1,553,000 | $-13,333,000 | $2,396,000 |
| Change In Inventory | $-14,947,000 | $56,895,000 | $40,973,000 | $-57,204,000 |
| Change In Receivables | $-17,165,000 | $-14,031,000 | $-3,312,000 | $-3,596,000 |
| Changes In Account Receivables | $-17,165,000 | $-14,031,000 | $-3,312,000 | $-3,596,000 |
| Other Non Cash Items | $-6,785,000 | $22,145,000 | $-27,123,000 | $-27,014,000 |
| Stock Based Compensation | $32,605,000 | $48,070,000 | $25,575,000 | $27,316,000 |
| Deferred Tax | $-3,373,000 | $-16,790,000 | $1,175,000 | $-1,352,000 |
| Deferred Income Tax | $-3,373,000 | $-16,790,000 | $1,175,000 | $-1,352,000 |
| Depreciation Amortization Depletion | $96,956,000 | $86,562,000 | $86,114,000 | $57,012,000 |
| Depreciation And Amortization | $96,956,000 | $86,562,000 | $86,114,000 | $57,012,000 |
| Depreciation | $96,956,000 | $86,562,000 | $86,114,000 | $57,012,000 |
| Net Income From Continuing Operations | $48,894,000 | $-25,514,000 | $35,596,000 | $185,959,000 |
| Interest Paid Supplemental Data | - | $6,070,000 | $988,000 | $1,033,000 |
| Income Tax Paid Supplemental Data | - | $19,298,000 | $26,963,000 | $34,365,000 |
| Gain Loss On Sale Of PPE | - | $3,596,000 | $0 | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
Fetched: 2026-06-16